ALIGOS Therapeutics: Review of ALG-000184 Late Breaker Data (HBV, Phase 1), from The Liver Meeting®, and KOL Perspective on Emerging HBV Therapies
About The Event
Join us for a virtual KOL event with ALIGOS Therapeutics, featuring Mark Sulkowski, MD (Johns Hopkins University School of Medicine) to review the Late Breaking results and next steps for ALG-000184, in Phase 1, and the unmet need and current treatment landscape for patients with chronic Hepatitis B (CHB).
The Phase 1 data are being featured being featured in a late breaking poster session at the American Association of Liver Disease’s annual Liver Meeting® on November 13, 2023 (poster #5028-C).
A live question and answer will follow the formal presentation.